NCT00223951

Safety Study of Ophthalmic Solution in Healthy, Normal Volunteers

A Multi-Center, Randomized, Double-Masked, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of R89674 0.25% Ophthalmic Solution in Healthy, Normal Volunteers

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 900 (planned)
• Sponsor: Vistakon Pharmaceuticals · Industry
• Sex: All
• Age: 3 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate the safety of R89674 0.25% ophthalmic solution in healthy normal volunteers

Conditions

• Healthy Volunteers Eligible for Study; Drug Being Developed for Allergic Conjunctivitis

Interventions

Type	Name	Description
DRUG	R89674 (generic name not yet established)

Timeline

• Start date: 2005-09-01
• Primary completion: 2005-12-01
• First posted: 2005-09-22
• Last updated: 2015-02-20

Locations

6 sites across 1 country: United States